ReviewClinical and translational radiation oncology2024
Reirradiation - still navigating uncharted waters?
Review in Clinical and translational radiation oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Reirradiation of lower gastrointestinal Cancer: A survey of ongoing trials by the Reirradiation Collaborative group (ReCOG).Technical innovations & patient support in radiation oncology · 2026Article
- Early Identification and Management of Biochemical Recurrence Following Radical Prostatectomy.Annals of surgical oncology · 2026Review
- A dedicated institutional clinical workflow and peer-review meeting for reirradiation.Technical innovations & patient support in radiation oncology · 2026Article
- A reirradiation workflow for managing patients with treatments planned in a multi-TPS environment.Technical innovations & patient support in radiation oncology · 2026Article
- Review
- Daily adaptive MR-guided stereotactic ablative re-irradiation (re-SABR) in oligometastatic liver disease: A single-institution retrospective analysis.Clinical and translational radiation oncology · 2026Article
- Multi-institutional virtual peer review for reirradiation: dedicated workflow and one-year results.Technical innovations & patient support in radiation oncology · 2025Article
- Enhancing Expertise in Reirradiation: Results from a Training Workshop Organized by Unicancer, the Federation of French Cancer Centers.Journal of cancer education : the official journal of the American Association for Cancer Education · 2025Article
- Reirradiation clinical practice in gastrointestinal abdominal malignancies: an international reirradiation collaborative group (ReCOG) systematic review.Clinical and translational radiation oncology · 2025Review
- Evaluation of tattoo reliability in breast cancer re-irradiation.Technical innovations & patient support in radiation oncology · 2025Article
- Radiation therapist (RTT) perspectives on developing image-guided radiotherapy (IGRT) protocols for reirradiation.Technical innovations & patient support in radiation oncology · 2025Article
- Developing and sustaining a secure application for transfer of previous radiation therapy treatment details.Technical innovations & patient support in radiation oncology · 2025Article
- Acute toxicity and quality of life in dose-escalated proton reirradiation for locally recurrent rectal cancer: The prospective ReRad II trial.Clinical and translational radiation oncology · 2025Review
- Reirradiation: Standards, challenges, and patient-focused strategies across tumor types.CA: a cancer journal for cliniciansReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the emergence of high-precision radiotherapy technologies such as stereotactic ablative radiotherapy (SABR), MR guided brachytherapy, image guided intensity modulated photon and proton radiotherapy and most recently daily adaptive radiotherapy, reirradiation is increasingly recognized as a viable treatment option for many patients. This includes those with recurrent, metastatic or new malignancies post initial radiotherapy. The primary challenge in reirradiation lies in balancing tumor control against the risk of severe toxicity from cumulative radiation doses to previously irradiated normal tissue. Although technology for precise delivery has advanced at a fast pace, clinical practice of reirradiation still mostly relies on individual expertise, as prospective evidence is scarce, the level of reporting in clinical studies is not standardized and of low quality - especially with respect to cumulative doses received by organs at risk. A recent ESTRO/EORTC initiative proposed a standardized definition of reirradiation and formulated general requirements for minimal reporting in clinical studies [1]. As a consequence we found it timely to convene for an international and interdisciplinary meeting with experts in the field to summarize the current evidence, identify knowledge gaps and explore which best practices can be derived for safe reirradiation. The meeting was held on 15.06.2023 in Zurich and was endorsed by the scientific societies SASRO, DEGRO and ESTRO. Here, we report on available evidence and research priorities in the field of reirradiation, as discussed during the meeting.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.